Table 1.
Relationship between vaccine efficacy (VE) and vaccine preventable disease incidence (VPDI) in selected vaccine clinical trials.
| Vaccine trial | Outcome with highest VE
|
Outcome with lowest, statistically significant VE
|
||||||
|---|---|---|---|---|---|---|---|---|
| Outcome | Incidence controlsa | VE | VPDIa | Outcome | Incidence controlsa | VE | VPDIa | |
| Indonesia Hib vaccine (4) | Culture-confirmed Hib meningitis | 0.19 | 86% | 0.16 | Clinical pneumonia | 395 | 4.0% | 15.8 |
| Gambia PCV(5) | Vaccine-serotype IPDb | 2.5 | 77% | 1.9 | Clinical pneumonia | 249 | 7% | 17.0 |
| Kenya rotavirus vaccine (7) | Severe rotavirus gastroenteritis attending health facility (1st year) | 40 | 83% | 33 | Gastroenteritis with severe dehydration reported at home (1st year) | 550 | 34% | 190 |
a
All incidences and VPDIs are given as per 1000 person-years.
b
IPD, invasive pneumococcal disease.